利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

648 条记录 (耗时 0.06 秒)

    Antiviral oligonucleotides
    111.
    发明申请
    Antiviral oligonucleotides 审中-公开
    抗病毒寡核苷酸

    公开(公告)号：US20060135458A1

    公开(公告)日：2006-06-22

    申请号：US11254920

    申请日：2005-10-19

    申请人： Andrew Vaillant ,  Jean-Marc Juteau

    发明人： Andrew Vaillant ,  Jean-Marc Juteau

    IPC分类号： A61K48/00 ,  C07H21/02

    CPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/06 ,  C12N15/11 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/351 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  A61K2300/00 ,  C12N2310/3521

    摘要： Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length and include chemical modifications, such as modified internucleotidic linkages and modifications at the 2′-position of the ribose moieties. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least one oligonucleotide that act by a sequence complementary mode of action.

    摘要翻译： 描述了具有抗病毒活性的随机序列寡核苷酸及其作为抗病毒剂的用途。 在许多情况下，寡核苷酸长度大于40个核苷酸，并且包括化学修饰，例如修饰的核苷间键和在核糖部分的2'-位的修饰。 还描述了用于预防或治疗人或动物中的病毒感染的方法，以及用于预防人类或动物中由佐剂病毒引起的癌症的方法。 所述方法通常涉及对需要这种治疗的人或动物施用药理学上可接受的治疗有效量的至少一种通过序列互补作用模式起作用的寡核苷酸。

    Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
    112.
    发明授权
    Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect 失效
    非诺贝特和/或非诺贝特衍生物的自乳化制剂具有改善的口服生物利用度和/或降低的食物效应

    公开(公告)号：US07022337B2

    公开(公告)日：2006-04-04

    申请号：US10607719

    申请日：2003-06-27

    申请人： Likan Liang ,  Amir H. Shojaei ,  Scott A. Ibrahim ,  Beth A. Burnside

    发明人： Likan Liang ,  Amir H. Shojaei ,  Scott A. Ibrahim ,  Beth A. Burnside

    IPC分类号： A61K9/48

    CPC分类号： A61K9/4866 ,  A61K9/1075 ,  A61K9/4858 ,  A61K31/216 ,  Y02A50/393

    摘要： A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.

    摘要翻译： 与可商购获得的制剂相比，具有改善的生物利用度的贝特类自乳化口服制剂与含有治疗有效剂量的非诺贝特，非诺贝特衍生物或其混合物的溶解在选自2-吡咯烷酮N-烷基衍生物，单 - 或二 - 或聚乙二醇单醚，C 8-12脂肪酸丙二醇的单酯或二酯或其组合，一种或多种表面活性剂和任选的一种或多种稳定剂，其可用于治疗高胆固醇血症或 哺乳动物在喂食或禁食状态下的高甘油三酯血症。

    Antiviral oligonucleotides targeting RSV
    115.
    发明申请
    Antiviral oligonucleotides targeting RSV 审中-公开
    针对RSV的抗病毒寡核苷酸

    公开(公告)号：US20040229828A1

    公开(公告)日：2004-11-18

    申请号：US10661415

    申请日：2003-09-12

    申请人： Replicor, Inc.

    发明人： Andrew Vaillant ,  Jean-Marc Juteau

    IPC分类号： A61K048/00

    CPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/06 ,  C12N15/11 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/351 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  A61K2300/00 ,  C12N2310/3521

    摘要： Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

    摘要翻译： 描述了具有抗病毒活性的随机序列寡核苷酸及其作为抗病毒剂的用途。 在许多情况下，寡核苷酸长度大于40个核苷酸。 还描述了用于预防或治疗人或动物中的病毒感染的方法，以及用于预防人类或动物中由佐剂病毒引起的癌症的方法。 所述方法通常涉及向需要这种治疗的人或动物施用药理学上可接受的治疗有效量的至少不受序列互补作用模式作用的寡核苷酸。

    Antiviral oligonucleotides targeting HSV and CMV
    116.
    发明申请
    Antiviral oligonucleotides targeting HSV and CMV 审中-公开
    针对HSV和CMV的抗病毒寡核苷酸

    公开(公告)号：US20040162254A1

    公开(公告)日：2004-08-19

    申请号：US10661097

    申请日：2003-09-12

    申请人： Replicor, Inc.

    发明人： Andrew Vaillant ,  Jean-Marc Juteau

    IPC分类号： A61K048/00

    CPC分类号： C12N15/115 ,  A61K31/7088 ,  A61K38/00 ,  A61K45/06 ,  C12N15/11 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/351 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  A61K2300/00 ,  C12N2310/3521

    摘要： Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

    摘要翻译： 描述了具有抗病毒活性的随机序列寡核苷酸及其作为抗病毒剂的用途。 在许多情况下，寡核苷酸长度大于40个核苷酸。 还描述了用于预防或治疗人或动物中的病毒感染的方法，以及用于预防人类或动物中由甲基病毒引起的癌症的方法。 所述方法通常涉及向需要这种治疗的人或动物施用药理学上可接受的治疗有效量的至少不受序列互补作用模式作用的寡核苷酸。

    Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
    117.
    发明申请
    Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases 审中-公开
    核苷，其制备和用作rna病毒聚合酶的抑制剂

    公开(公告)号：US20040138170A1

    公开(公告)日：2004-07-15

    申请号：US10471056

    申请日：2004-03-03

    发明人： John A. Montgomery ,  Yarlagadda S Babu ,  Pooran Chand ,  R Scott Rowland

    IPC分类号： A61K031/7072 ,  A61K031/52 ,  A61K031/513

    CPC分类号： C07H19/20 ,  A61K31/513 ,  A61K31/52 ,  A61K31/7072 ,  A61K38/21 ,  A61K45/06 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  Y02A50/393 ,  Y02A50/465 ,  A61K2300/00

    摘要： The compounds represented by the formulae (I) wherein X is selected from the group consisting of: O, S, NnullR1, and CHR1; Y and Ynull is individually selected from H, OR1, NR1R2, and N3 Z and Znull is individually selected from II, OR1, and NR1R2 RnullII, formula (II), formula (III), or formula (III), R1 and R2 is selected from H, alkyl, acyl, aryl which may be substituted or unsubstituted, R3 is selected from H, alkyl, alkenyl, alkynyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl, B is selected from 5 or 6-substituted uracil or cytosine, pseudouracil, N-substituted pseudouracil, 2-thiouracil, 2-thiocytosine, 5- or 6-substituted 2-thiouracil and 2-thiocytosine, 6-azauracil, 5-azacytosine, 8-azapurines, and 7-aza-8-deazapurines. Substitutions may be halosubstituted alkyl, halosubstituted alkenyl, halosubstituted alkynyl, halosubstituted aryl, alkylthio, or NR1R2. When Z and Znull are H and Y or Ynull is OH then B is not 5-methyl uracil or cytosine; and pharmaceutically acceptable salts thereof, mono, di or triphosphate and prodrugs thereof. 1

    摘要翻译： 由式（I）表示的化合物，其中X选自：O，S，N-R 1和CHR 1; Y和Y'分别选自H，OR 1，NR 1 R 2，N 3 Z和Z'分别选自II，OR 1和NR 1 R 2， R = II，式（II），式（III）或式（III），R 1和R 2选自H，烷基，酰基，可被取代或未取代的芳基，R 3， 选自H，烷基，烯基，炔基，芳基，酰氧基烷基和新戊酰氧基烷基，B选自5或6位取代的尿嘧啶或胞嘧啶，假尿嘧啶，N-取代的假尿嘧啶，2-硫尿嘧啶，2-硫代胞嘧啶，5-或6 2-取代的2-硫尿嘧啶和2-硫代胞嘧啶，6-氮尿嘧啶，5-氮杂胞嘧啶，8-氮杂嘌呤和7-氮杂-8-脱氮嘌呤。 取代的可以是卤代烷基，卤代烯基，卤代炔基，卤代芳基，烷硫基或NR 1 R 2。 当Z和Z'为H且Y或Y'为OH时，B不为5-甲基尿嘧啶或胞嘧啶; 其药学上可接受的盐，单，二或三磷酸及其前体药物。

    Methods for treating viral infection using IL-28 and IL-29
    118.
    发明申请
    Methods for treating viral infection using IL-28 and IL-29 有权
    使用IL-28和IL-29治疗病毒感染的方法

    公开(公告)号：US20040138122A1

    公开(公告)日：2004-07-15

    申请号：US10691923

    申请日：2003-10-23

    发明人： Kevin M. Klucher ,  Pallavur V. Sivakumar ,  Wayne R. Kindsvogel ,  Katherine E. Henderson

    IPC分类号： A61K039/29

    CPC分类号： A61K47/48215 ,  A61K38/20 ,  A61K38/21 ,  A61K47/60 ,  C07K14/54 ,  Y02A50/385 ,  Y02A50/393

    摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

    摘要翻译： 已经显示IL-28A，IL-28B，IL-29及其某些突变体对病毒物种的光谱具有抗病毒活性。 特别感兴趣的是在感染肝脏的病毒（例如乙型肝炎病毒和丙型肝炎病毒）上显示的抗病毒活性。 此外，IL-28A，IL-28B，IL-29及其突变体在用干扰素治疗观察到的造血细胞上不表现出一些抗增殖活性。 没有伴随干扰素治疗的免疫抑制作用，IL-28A，IL-28B和IL-29可用于治疗免疫功能低下的病毒感染患者。

    Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
    120.
    发明申请
    Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect 失效
    非诺贝特和/或非诺贝特衍生物的自乳化制剂具有改善的口服生物利用度和/或降低的食物效应

    公开(公告)号：US20040110842A1

    公开(公告)日：2004-06-10

    申请号：US10607719

    申请日：2003-06-27

    发明人： Likan Liang ,  Amir H. Shojaei ,  Scott A. Ibrahim ,  Beth A. Burnside

    IPC分类号： A61K031/194

    CPC分类号： A61K9/4866 ,  A61K9/1075 ,  A61K9/4858 ,  A61K31/216 ,  Y02A50/393

    摘要： A fibrate self-emulsifying oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate, derivative of fenofibrate or mixtures thereof dissolved in a fibrate solubilizer selected from N-alkyl derivative of 2-pyrrolidone, mono- or di- or polyethylene glycol monoethers, C8-12 fatty acid mono- or di-esters of propylene glycol, or combinations thereof, one or more surfactants and optionally one or more stabilizers useful in the treatment of hypercholesterolaemia or hypertriglyceridaemia in mammals in the fed or fasted state.

    摘要翻译： 与可商购获得的制剂相比，具有改善的生物利用度的贝特类自乳化口服制剂与含有治疗有效剂量的非诺贝特，非诺贝特衍生物或其混合物的溶解在选自2-吡咯烷酮N-烷基衍生物，单 - 或二 - 或聚乙二醇单醚，丙二醇的C8-12脂肪酸单酯或二酯或其组合，一种或多种表面活性剂和任选的一种或多种用于治疗哺乳动物或哺乳动物中的高胆固醇血症或高甘油三酯血症的稳定剂 州。